Lidodepomedrol (Lidocaine Hydrochloride Monohydrate, Methylprednisolone Acetate)

Lidocaine blocks voltage‑gated sodium channels on peripheral nerves, stopping the transmission of pain signals. Methylprednisolone acetate binds to glucocorticoid receptors inside cells, altering gene expression to suppress inflammatory mediators, reduce swelling, and modulate immune responses. Together they give rapid analgesia and sustained inflammation control.

The specific dose of Lidodepomedrol is determined by the prescribing clinician based on the indication, site of injection, patient weight, and clinical response. Healthcare professionals calculate the appropriate volume and concentration to achieve the desired therapeutic effect while adhering to safety guidelines.

Safety data for Lidodepomedrol in pregnancy and lactation are limited. Because it contains a corticosteroid, it should be used only if the potential benefit justifies any potential risk to the fetus or infant. Clinicians should evaluate each case individually and discuss alternatives when possible.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Lidodepomedrol combines lidocaine, a short‑acting local anesthetic, with methylprednisolone acetate, a long‑acting glucocorticoid. Compared with products that use shorter‑acting steroids (e.g., triamcinolone), it may provide a more prolonged anti‑inflammatory effect, while the lidocaine component offers immediate pain relief. Choice depends on the desired duration of action and physician preference.

Lidodepomedrol should be stored below 25 °C in its original packaging, protected from moisture and direct light. Do not freeze the product. Ensure that the vial remains sealed until use to maintain sterility and potency.

The product is supplied as a sterile injectable solution and is administered by a qualified healthcare professional. The injection is performed directly into the joint (intra‑articular), bursa (intrabursal) or lesion (intralesional) using aseptic technique, with the volume and site selected according to the clinical indication.

Serious risks include local infection at the injection site, systemic corticosteroid effects such as hyperglycaemia or adrenal suppression, allergic reactions that can progress to anaphylaxis, tendon or cartilage damage with repeated injections, and significant bleeding in patients on anticoagulant therapy. Prompt medical attention is required if any of these occur.

Lidodepomedrol is contraindicated in patients with known hypersensitivity to lidocaine, methylprednisolone acetate, or any formulation excipients. It should also be avoided in individuals with active infection at the intended injection site, uncontrolled diabetes, severe osteoporosis, or those who have had recent joint surgery where steroid use is discouraged.